NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 10, 2016, Pages 1364-1369

  Wattanapokayakit, S ^a,i   Mushiroda, T ^b   Yanai, H ^c   Wichukchinda, N ^a   Chuchottawon, C ^a   Nedsuwan, S ^a   Rojanawiwat, A ^a   Denjanta, S ^a   Kantima, T ^d   Wongyai, J ^d   Suwankesawong, W ^e   Rungapiromnan, W ^e   Kidkeukarun, R ^f   Bamrungram, W ^g   Chaiwong, A ^h   Suvichapanich, S ⁱ   Mahasirimongkol, Surakameth ^a   Tokunaga, K ⁱ  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b Institute of Physical and Chemical Research   (Japan)

^c Japan Anti Tuberculosis Association   (Japan)

^d TB HIV Research Foundation   (Thailand)

^e The Food and Drug Administration Thailand Ministry of Public Health   (Thailand)

^f BUDDHACHINARAJ HOSPITAL   (Thailand)

^g Rayong Hospital   (Thailand)

^h Medical Technology Group   (Thailand)

ⁱ UNIVERSITY OF TOKYO   (Japan)

Author keywords

Anti tuberculosis drug induced liver injury; DILI; NAT2

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; PYRAZINAMIDE; TUBERCULOSTATIC AGENT; ISONIAZID; NAT2 PROTEIN, HUMAN;

ACETYLATOR PHENOTYPE; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAT2 GENE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; THAI (CITIZEN); TOXIC HEPATITIS; TUBERCULOSIS; ACETYLATION; AGED; CASE CONTROL STUDY; DNA SEQUENCE; GENE FREQUENCY; GENETICS; GENOTYPING TECHNIQUE; METABOLISM; PREVALENCE; THAILAND;

ACETYLATION; ADULT; AGED; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; CHEMICAL AND DRUG INDUCED LIVER INJURY; FEMALE; GENE FREQUENCY; GENOTYPING TECHNIQUES; HAPLOTYPES; HUMANS; ISONIAZID; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; RISK FACTORS; SEQUENCE ANALYSIS, DNA; THAILAND; TUBERCULOSIS;

EID: 84987625435     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.15.0310     Document Type: Article

References (30)

1. World Health Organization. WHO global tuberculosis report, 2014. WHO/HTM/TB/2014.08. Geneva, Switzerland: WHO, 2014.
2. World Health Organization. Tuberculosis in the South-East Asia Region. SEA/TB/338. Geneva, Switzerland: WHO, 2012. http://reliefweb.int/sites/reliefweb.int/files/resources/Tuberculosis-WHO-TB-Report-2012.pdf. Accessed January 2016.
3. Pasipanodya J G, Gumbo T. A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple antituberculosis drugs. Curr Opin Pharmacol 2011; 11: 457-463.
4. Pasipanodya J, Srivastava S, Gumbo T. New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2012; 56: 5428.
5. Srivastava S, Pasipanodya J G, Meek C, Leff R, Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204: 1951-1959.
6. Thongraung W, Sittidach M, Khwansuwan P, Sariyasuntorn K, Wongsampan S. Evaluation of the physicians' approach to the diagnosis and treatment of patients with antituberculosis drug-induced hepatotoxicity. J Eval Clin Pract 2012; 18: 1119-1125.
7. Walraven J M, Zang Y, Trent J O, Hein D W. Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2. Curr Drug Metab 2008; 9: 471-486.
8. Doll M A, Hein D W. Comprehensive human NAT2 genotype method using single nucleotide polymorphism-specific polymerase chain reaction primers and fluorogenic probes. Anal Biochem 2001; 288: 106-108.
9. Zhao B, Lee E J, Wong J Y, Yeoh P N, Gong N H. Frequency of mutant CYP1A1, NAT2 and GSTM1 alleles in normal Indians and Malays. Pharmacogenetics 1995; 5: 275-280.
10. Lin H J, Han C Y, Lin B K, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, Blacks, Hispanics, and whites: application to metabolic epidemiology. Am J Hum Genet 1993; 52: 827-834.
11. Bell D A, Taylor J A, Butler M A, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993; 14: 1689-1692.
12. Bechtel Y C, Bechtel P R, Lelouet H, Choisy H, Dy N R. [The acetylator polymorphism in a Khmer population: clinical consequences]. Thérapie 2001; 56: 409-413. [French]
13. Lin H J, Han C Y, Lin B K, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994; 4: 125-134.
14. Woolhouse N M, Qureshi M M, Bastaki S M, Patel M, Abdulrazzaq Y, Bayoumi R A. Polymorphic N-acetyltransferase (NAT2) genotyping of Emiratis. Pharmacogenetics 1997; 7: 73-82.
15. Andrade R J, Agundez J A, Lucena M I, Martinez C, Cueto R, Garcia-Martin E. Pharmacogenomics in drug induced liver injury. Curr Drug Metab 2009; 10: 956-970.
16. Lee S W, Chung L S, Huang H H, Chuang T Y, Liou Y H, Wu L S. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis 2010; 14: 622-626.
17. Vuilleumier N, Rossier M F, Chiappe A, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006; 62: 423-429.
18. Higuchi N, Tahara N, Yanagihara K, et al. NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J Gastroenterol 2007; 13: 6003-6008.
19. Huang Y S, Chern H D, Su W J, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-889.
20. Teixeira R L, Morato R G, Cabello P H, et al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz 2011; 106: 716-724.
21. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11: 272-276.
22. Soejima M, Sugiura T, Kawaguchi Y, et al. Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus. Arthritis Res Ther 2007; 9: R23.
23. Kukongviriyapan V, Lulitanond V, Areejitranusorn C, Kongyingyose B, Laupattarakasem P. N-acetyltransferase polymorphism in Thailand. Hum Hered 1984; 34: 246-249.
24. Nickerson D A, Tobe V O, Taylor S L. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res 1997; 25: 2745-2751.
25. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995; 57: 581-592.
26. Deguchi T, Mashimo M, Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem 1990; 265: 12 757-12 760.
27. Gross M, Kruisselbrink T, Anderson K, et al. Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev 1999; 8: 683-692.
28. Rattanavipapong W, Koopitakkajorn T, Praditsitthikorn N, Mahasirimongkol S, Teerawattananon Y. Economic evaluation of HLA-B∗15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Epilepsia 2013; 54: 1628-1638.
29. Hosono N, Chantarangsu S, Kiyotani K, et al. Development of new HLA-B∗3505 genotyping method using Invader assay. Pharmacogenet Genomics 2010; 20: 630-633.
30. Azuma J, Ohno M, Kubota R, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol 2013; 69: 1091-1101.